GeneDx Holdings Corp. (WGS)
| Market Cap | 1.96B |
| Revenue (ttm) | 267.23M |
| Net Income (ttm) | -83.50M |
| Shares Out | 27.47M |
| EPS (ttm) | -3.16 |
| PE Ratio | n/a |
| Forward PE | 180.60 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 88,899 |
| Open | 73.95 |
| Previous Close | 73.73 |
| Day's Range | 70.60 - 74.41 |
| 52-Week Range | 1.29 - 89.11 |
| Beta | 2.18 |
| Analysts | Strong Buy |
| Price Target | 67.00 (-5.97%) |
| Earnings Date | Oct 29, 2024 |
About WGS
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Cor... [Read more]
Financial Performance
In 2023, GeneDx Holdings's revenue was $202.57 million, a decrease of -13.69% compared to the previous year's $234.69 million. Losses were -$175.77 million, -67.98% less than in 2022.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for WGS stock is "Strong Buy." The 12-month stock price forecast is $67.0, which is a decrease of -5.97% from the latest price.
News
New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the results of an extensive study shedding light on th...
GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American Soci...
Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds
The precision medicine market is projected to grow from $91.72 billion in 2024 to $246.3 billion by 2033, fueled by advancements in genomic technologies. In the last year, Natera, Inc. and GeneDx Hold...
GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term
GeneDx Holdings Corp. stock has risen by a scarcely believable >3,000% across the past year. The company provides exome sequencing products that can be used to search for and diagnose hundreds of gene...
GeneDx Holdings Corp. (WGS) Q3 2024 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - President and Chief Execu...
Genetic Testing Firm GeneDx Reports Narrower Q3 Loss As Revenues Surge, Lifts Annual Guidance
GeneDx Holdings WGS stock is trading higher on Tuesday.
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2024.
Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that JAMA, the Journal of the American Medical Associa...
GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists
GeneDx Holdings Corp. leverages its genomic and data science expertise to provide precise medical diagnostics, focusing on rare diseases and pediatric exome/genome testing. The company's second-quarte...
GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it has provided genomic newborn screenings (gNBS) for ...
GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx today announced it will release financial results for the third quarter of 2024 before the market opens on Tuesday, October 29, 2024.
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that the compensation committee of GeneDx's board of directors granted restricted stock units (“RSUs”).
GeneDx Holdings: Profits On The Horizon For AI Driven Health Platform
GeneDx Holdings is poised for profitability in the near future. GeneDx is benefitting from increased volume and improved average reimbursement rates. The company's double-digit revenue growth and soon...
GeneDx to Participate in Fall Investor Conferences
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that company management will participate in upcoming investor conferences this fall.
GeneDx Holdings Corp. (WGS) Q2 2024 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Sabrina Dunbar - Commercial Chief of Staff Katherine Stueland - President and Chief E...
GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the second quarter of 2024.
GeneDx Announces Whole Genome Sequencing (WGS) Product Enhancements to Accelerate Diagnoses for More Patients
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx announces enhancements to its Whole Genome Sequencing, aiming to accelerate diagnoses and shorten the diagnostic odyssey for patients.
GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024
GeneDx (Nasdaq: WGS) today announced it will release financial results for the second quarter of 2024 after the market closes on Tuesday, July 30, 2024.
Stock Ideas Amid Investor Optimism
The latest Investopedia survey shows that investors' optimism is rising. Readers are as optimistic about the stock market as they've been in the past 12 months, notes Caleb Silver.
GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients
-- New integration to streamline access for health systems and improve provider and patient journeys using Epic for electronic connections -- -- Increases commercial footprint and focus on acceleratin...
GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing
GeneDx Holdings Corp. focuses on delivering precise medical diagnostic outcomes through its genomic expertise and rare disease dataset. Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) a...
GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients
STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access ...
GeneDx to Participate in Upcoming Investor Conferences
STAMFORD, Conn., May 22, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participa...
GeneDx Holdings Corp. (WGS) Q1 2024 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS) Q1 2024 Earnings Conference Call April 29, 2024 4:30 PM ET Company Participants Sabrina Dunbar - Commercial Chief of Staff Katherine Stueland - President and Chief ...
GeneDx Reports First Quarter 2024 Financial Results and Business Highlights
Reported first quarter 2024 revenue from continuing operations 1 of $61.5M with 96% year-over-year growth of exome and genome test revenue Expanded first quarter 2024 adjusted gross margins 2 from con...